Not independent
Tenure on this board
2.7 yrs
Meeting calendar
LXEO · Annual meeting · Thursday, June 25, 2026
Lexeo Therapeutics Inc
3 nominees · 2 ballot items.
Elect three Class III directors (R. Nolan Townsend, Brenda Cooperstone and Paula HJ Cholmondeley) to serve until the 2029 annual meeting; and ratify the appointment of KPMG LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
Market cap
$372M
1Y TSR
+11.7%
Board grade
D
Record date
May 7, 2026
Filing
DEF 14A
Meeting concluded · Jun 25, 2026
Follow how the vote landed and what changed on Lexeo Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class III Directors (R. Nolan Townsend, Brenda Cooperstone and Paula HJ Cholmondeley
ManagementBoard: FORElect three Class III directors—R. Nolan Townsend, Brenda Cooperstone, and Paula HJ Cholmondeley—to hold office until the 2029 annual meeting and until their successors are elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm (KPMG LLP
ManagementBoard: FORRatify the appointment of KPMG LLP as Lexeo Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
4.7 yrs
Independent
Tenure on this board
3.0 yrs
Also a director at
Senti Biosciences Holdings Inc (SNTI)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 7.9% | 6,184,134 | $35M |
| 2 | Affinity Asset Advisors, LLC | 6.4% | 5,050,211 | $29M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 6.4% | 5,000,000 | $29M |
| 4 | JANUS HENDERSON GROUP PLC | 6.3% | 4,963,503 | $28M |
| 5 | Vestal Point Capital, LP | 5.7% | 4,475,000 | $26M |
| 6 | Frazier Life Sciences Management, L.P. | 5.6% | 4,424,725 | $25M |
| 7 | CITADEL ADVISORS LLC | 4.7% | 3,687,967 | $21M |
| 8 | ORBIMED ADVISORS LLCActivist | 4.6% | 3,602,450 | $21M |
| 9 | STATE STREET CORP | 4.5% | 3,568,242 | $20M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 3,007,093 | $17M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Lexeo Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$428M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Lexeo Therapeutics Inc 2026 annual meeting?
- Lexeo Therapeutics Inc (LXEO) holds its 2026 annual shareholder meeting on Thursday, June 25, 2026.
- What is the record date for the Lexeo Therapeutics Inc 2026 meeting?
- The record date for the Lexeo Therapeutics Inc 2026 meeting is Thursday, May 7, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Lexeo Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Lexeo Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Lexeo Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Lexeo Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.